Sitagliptin (Januvia™) is a new oral agent ... including T-cell activation and proliferation. Although the mechanism of action may indicate that DPP-4 inhibition is a promising treatment for ...

A deeper dive into data from the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS ... thought to be the main mechanism by which the drug lowered cardiovascular deaths, since ...

The new oral antidiabetic drugs sitagliptin and vildagliptin work by boosting the gut’s incretin hormones GLP-1 and GIP to regulate insulin secretion following food intake and glucagon secretion when ...

Treatment modalities for advanced solid pseudopapillary tumor of the pancreas. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text ...